Business Wire: Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent gadoquatrane presented as late-breaking data during a scientific session at the 2025 European ...
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025: